PFIZER Aktie

 

Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike. JNJ raised guidance while headlines fixated on a 68,000-case talc litigation MDL. Pfizer reaffirmed its outlook and pushed harder into obesity and oncology. Two large-cap dividend payers, two very different setups for buyers today. ... Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King...

Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look....

Die ehemalige Pfizer-Zentrale in Manhattan wird nach akuter Einsturzgefahr stabilisiert. Das Drama verheißt nichts Gutes für groß angelegte Umbauprojekte am US-Immobilienmarkt....

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies....

Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch. Padcev Carries Pfizer. Biosimilars Bite Amgen. Pfizer's oncology ... Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen...

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average....

Round led by Index Ventures, alongside Kleiner Perkins, Sequoia Capital, Dimension and existing investors, values company at $3.8B Chai's AI models generate new molecular designs from scratch, helping partners including Eli Lilly and Pfizer pursue targets that traditional discovery methods struggle to reach SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the company engineering AI models to discover new molecules, today announced a $400M Series C fundraise to further accelerate progress. The round, which values the company at $3.8B, was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital and Dimension. These firms were joined by new investors Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, and other notable investors. Existing investors Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite also joined the round. Chai Discovery builds AI models to accelerate pre-clinical drug di...

Germany Stops Recommending COVID-19 Vaccination For Most People Under 75 Authored by Zachary Stieber via The Epoch Times, Germany has updated its COVID-19 vaccination recommendations, advising most people under 75 not to receive a COVID-19 vaccine. A health worker at a mobile COVID-19 vaccination station in a shopping mall fills a syringe with the Pfizer-BioNTech vaccine in Ludwigsburg, Germany, on Nov. 11, 2021. Thomas Kienzle/AFP via Getty Images Germany's Standing Committee on Vaccination, which offers vaccine recommendations for the country, on July 9 said in a 33-page document that its stance on COVID-19 vaccination was changing "to reflect the current epidemiological situation and the population's immune status." The committee, known as STIKO, added: "A large proportion of the adult population now has hybrid immunity, characterised by exposure to a variety of antigenic contacts, and is therefore sufficiently well protected against severe cases of COVID-19. "This als...

Drug pricing matters, but pipelines matter even more....

In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day....

Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is a slow-moving trap waiting to spring....

Charlotte (www.aktiencheck.de) - Pfizer-Aktienanalyse der Bank of America (BofA): BofA habe das Kursziel für die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) von 27 auf 26 USD gesenkt und das "neutral"-Rating bestätigt. Nach Einschätzung der Analysten dürften die Ergebnisse für das zweite Quartal zeigen, dass Pharmakonzerne mit hochwertigen Medikamentenportfolios und nachhaltigen Wachstumstreibern weiterhin eine stärkere Entwicklung aufweisen würden. [mehr]...

Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility....

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off....

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Pfizer mit einem Kursziel von 25 US-Dollar auf "Sector Perform" belassen. Seine Umsatzschätzung entspreche dem Konsens, schrieb Trung Huynh am Freitag in seinem Ausblick auf ......

Both McDonald's and Pfizer are blue-chip laggards trading at a discount, both cut reliable dividend checks, and both promise retirees a place to park serious money. But one of them carries hidden risks that could quietly wreck an income portfolio....

Poland and Romania's legal battles with Pfizer Inc. over unused Covid-19 vaccine purchases are spilling into the funding of the eastern European nations' air traffic agencies....

NYC Tower Owner Prepares To Rebuild 15 Floors After I-Beam Failure Fears of a possible collapse at a condo tower under construction near Grand Central Terminal had abated by the end of the week, but the incident only signals the massive engineering challenges tied to Manhattan's office-to-apartment conversion boom. The former Pfizer headquarters at 235 East 42nd Street, being converted by David Werner and Nathan Berman's Metro Loft Management into more than 1,600 residential units, has become a high-profile example of the risks of repurposing aging office towers into housing at scale to achieve socialist NYC Mayor Zohran Mamdani's strategy to address the metro area's housing shortage. Engineer: “The concrete beams in our residential conversion of the Pfizer Building are buckling. The building could collapse! Did you correctly account for the weight of the additional floors we added?” ChatGPT: “You're absolutely right! I see the issue now—in using the Euler… pic.twitter.com/Wh3...